Cerebral palsy (CP) results from a non-progressive injury to the developing central nervous system and is the most common cause of physical disability in children, with an incidence of 1.5 to 2.5 cases per 1000 live births. 1 Secondary musculoskeletal pathologies (namely muscle contractures and bony deformities) develop slowly in response to primary problems (namely muscle tone, balance, strength, and selective motor control of different muscle groups), producing severe motor dysfunction, leading to a requirement for multiple orthopaedic surgery. 2, 3 The aim of treatment in CP patients is to minimize the development of secondary problems by focusing on the reduction or normalization of tone, facilitating adequate stretch to muscles, and increasing the active range of motion to maximize function and delay or to obviate the need for surgery. 2, 3 Conservative treatments include physical and occupational therapy, orthotics, serial casting, and oral medication. [4] [5] [6] [7] [8] Botulinum toxin type A (BTX-A) is a relatively new treatment available for children with CP. This neurotoxin is injected intramuscularly and blocks the release of acetylcholine at the neuromuscular junction, causing selective, temporary muscular chemodenervation. When combined with casting, orthoses, and intensive physical therapy programmes, BTX-A allows stretching and improved motion, with benefits lasting 3 to 6 months. 9 Koman et al. 10 evaluated the effect of singlelevel BTX-A treatment on the requirement for surgery to lengthen the Achilles tendon and showed a delay of 3 years 10 months to surgery and a significantly older age at which Achilles tendon lengthening was performed after BTX-A treatment. There have been no studies on the long-term outcome of multilevel treatment with BTX-A; however, Bakheit et al. 11 concluded, from a study of 1594 BTX-A treatments in children with muscle spasticity, that multilevel treatments resulted in a better overall response than single-level treatments.
Since 1996 the multidisciplinary team of the University of Leuven, Pellenberg, Belgium, has routinely treated patients with CP by using BTX-A in accordance with an integrated multilevel approach (i.e. in combination with conservative treatment options), with the goal of achieving an optimal alignment of the legs and pelvis over one course of injections. 4 The long-term treatment goal has been to reduce and delay surgery until the child is older than 7 to 8 years of age, because of its high chance of failure and less predictable results due to immaturity of the motor capacities of the child, as well as differential growth patterns between the muscles, tendons, and bones in the younger child. 3, 12 The purpose of this study was to define the effects of BTX-A on the functional condition of 30 children (21 males, nine females) with CP treated in accordance with the best practice guidelines in paediatric orthopaedics. 2, 3, 9 It was hypothesized that optimally timed multilevel BTX-A treatment in children with CP improves gait patterns in the age range 5 to 10 years.
Method

PATIENTS
This nested case-control study comprised two groups (BTX-A and control). Patient selection was based on a retrospective review of patient medical records for children with CP treated regularly as outpatients between 1987 and 2001. Patients were included if they had predominantly spastic CP (i.e. hemiplegia or diplegia), long-term follow-up at the paediatric orthopaedic clinic, a well-documented clinical history, appropriate physiotherapy and occupational therapy, day and night orthoses, and at least one full three-dimensional gait analysis as part of their longitudinal evaluation.
The BTX-A group consisted of 30 children born between 1990 and 1993. Treatment comprised multiple sessions of multilevel BTX-A commencing at a young age, and as part of an integrated conservative treatment programme. 4 The control group consisted of 30 children (13 males, 17 females) born between 1987 and 1993 who were treated by the same multidisciplinary team; however, at the time of their motor development BTX-A was not available and could not be offered as potential therapy. All other care used the same integrated approach as for those patients who received BTX-A.
The two groups were matched to reduce the potential issue of selection bias; this was performed according to diagnosis, age at the time of the gait analysis, and the Gross Motor Function Classification System (GMFCS) level at the time of the first clinical examination. The children of both groups also received similar orthotic management and frequency of physiotherapy ( Table I ). The GMFCS defined at treatment outset was included to evaluate whether the two groups had similar motor capacities. This matching procedure was applied to ensure that the BTX-A treatment was an important variable affecting the final outcome of both groups. The GMFCS was scored retrospectively, on the basis of a detailed study of the available clinical reports.
Ethical approval for this study was obtained from the Ethics Committee of the University Hospital of Leuven, and consent was obtained from the parents.
STUDY DESIGN
All children received three-dimensional gait analysis to determine current status in motor development (including kinematics, kinetics, and surface electromyogram [EMG]) between 5 and 10 years of age. The mean age of the BTX-A group at the time of the gait analysis was 6 years 11 months (SD 1y 5mo) and for the control group it was 7 years 8 months (SD 1y 10mo).
Kinematic and kinetic measurements were collected with a six-camera VICON system and two AMTI forceplates (Advanced Mechanical Technology Inc., Watertown, MA, USA). Fifteen passive reflective markers were placed on specific lowerextremity bony landmarks of each patient. The patient was asked to walk at a comfortable speed down a 10m walkway and data were collected over three successful recordings. Kinetic data were collected for children who were walking unaided (23 children per group).
EMG data were collected by using surface electrodes on seven lower-extremity muscle groups. Muscle activity was detected with a 16-channel K-lab EMG system (Biometrics Europe, 1322 AD Almere, the Netherlands) and outputs of the rectus femoris, vastus lateralis, medial and lateral hamstrings, tibialis anterior, gastrocnemius, and soleus muscles were obtained. The raw EMG signals were high-pass filtered with a cut-off frequency of 20Hz (18 db/octave; Butterworth application), rectified and low-pass filtered at 25Hz to acquire the linear envelopes. Vicon Clinical Manager software (Oxford Metrics, Oxford, UK) was used to define gait cycles, determine temporal and stride parameters, and to estimate the joint angles, internal moments, and power.
For both groups, treatment goals were defined on the basis of objective measurements of pathological gait and clinical examination by the same multidisciplinary team (namely an orthopaedic surgeon, a neuropaediatrician, a rehabilitation physician, a physiotherapist, and a kinesiologist, at the University Hospital of Leuven, Pellenberg, Belgium). All children were treated individually in accordance with best practice paediatric orthopaedic guidelines, 2,3 including physical and occupational therapy, orthotic management, serial casting, and oral medication. Orthopaedic surgery was planned when severe secondary problems limited functionality.
All children in the BTX-A group received at least one session of BTX-A injections administered in accordance with the integrated multilevel approach. All treatments in this group had been recommended as a result of lack of progression in motor development, intolerance of day and night splinting, development of fixed muscle contractures, and/or a decrease in functionality. Various combinations of muscles were injected in each session: gastrocnemius, medial hamstrings, adductors, iliopsoas, tibialis posterior and, less often, the soleus, rectus femoris, lateral hamstrings, tensor fascia latae, and specific foot muscles. Each selected muscle was injected at multiple sites to a maximum of 50U per site, under anaesthesia. A dilution of 100U of Botox (Allergan, Inc., Irvine, CA, USA) in 2ml of saline was used. Dosage was calculated in accordance with the number of selected muscles and total body weight, and ranged between 14 and 31U/kg body weight for children with diplegia and between 6 and 23U/kg body weight for children with hemiplegia. 4, 13 Of the 30 children in the BTX-A group, 10 received one BTX-A session, 10 received two sessions, five received three sessions, and five received more than three sessions. The mean age at the first BTX-A treatment was 4 years 6 months (SD 1y 5mo). The mean time between the last BTX-A treatment and the gait analysis was 1 year 10 months (SD 10mo), thereby excluding the short-term therapeutic effect of any previous BTX-A treatment. None of the children had a history of orthopaedic surgery. Children in the control group underwent treatment before the availability of BTX-A; however, four of the 30 children received one BTX-A injection session when they were older (mean age 7y 5mo, range 6y 8mo-8y 5mo). With the exception of the BTX-A treatment, the control group was treated identically to the BTX-A group. Ten patients in the control group had undergone previous orthopaedic surgery (multilevel soft-tissue surgery in six cases and isolated Achilles tendon lengthening in four cases). None of the children received any surgical intervention during the year before the gait analysis. OUTCOME MEASURES Forty-eight parameters were selected in accordance with recommendations in the literature 14, 15 and based on the routine gait analysis protocol used at the Pellenberg University Hospital. Kinematic (joint angles, 20 parameters), kinetic (internal moments and power, 15 parameters) and EMG (linear envelope, 10 parameters) results were assessed, as well as time and distance parameters (namely cadence, velocity, and step length) for the affected side of children with hemiplegia and for a randomly selected side in children with diplegia (randomization was performed by computer model). The assessment of the gait parameters was undertaken by one trained independent kinesiologist. The assessor was blinded to the treatment allocated before the gait analysis (the gait analyses were randomly selected from the total group of children, including both the BTX-A group and the control group).
STATISTICAL ANALYSIS χ 2 and paired t-tests were used to evaluate any baseline differences between the groups (namely diagnosis, ambulation at young age, and a variety of conservative treatment conditions; Table I ).
In addition to standard summary statistics, including mean and SD, standardized variables were used to define the extent of pathology for each gait parameter. These z-scores for the continuous variables were defined for each parameter and for each participant, using the mean and SD of the paediatric normal database of the gait laboratory at the Pellenberg University Hospital to determine the extent of pathology (i.e. the difference from normal gait, taking into account the normal variation in gait parameters). This normal database comprised the gait parameters of 31 children aged between 3 and 6 years, without a history of paediatric orthopaedic or neuromuscular problems, and was evaluated with the use of the same gait analysis procedure as that described above. The age range between 3 and 6 years for the normal children was found to be functionally comparable with the patients in this study. The root mean square (RMS) of the z-scores was calculated to give a group mean extent of pathology for each parameter.
For continuous variables, a paired t-test was used to determine the significance in the average results between the two matched groups. For discrete variables, absolute and relative distributions of frequencies were calculated, and the Wilcoxon signed rank test was used to evaluate the differences between groups.
Analysis of covariance (ANCOVA) was conducted in the two groups to evaluate the possible influence of differences in baseline characteristics on final outcome; for example, diagnosis, GMFCS at initial clinical evaluation, and a variety of conservative treatment conditions, including age at time of gait analysis (Table I) . Statistical significance was set at p<0.05 (two-tailed).
Results
With regard to their baseline clinical characteristics, the BTX-A and control groups were similar in terms of diagnosis and GMFCS classification at the baseline clinical evaluation. The only difference of note was that intensive use of day orthoses was seen more often in the BTX-A group than in the control group (p<0.05). Apart from BTX-A, other conservative treatment conditions (night orthoses and physiotherapy) did not differ between the two groups. The control group was 10 months older than the BTX-A group at the time of gait evaluation (statistically significant according to a paired t-test; p<0.001). However, an ANCOVA in which the evaluation age and the use of day orthoses were taken as covariates indicated that these variables had no significant influence on the differences in gait parameters found between the groups (Table I) .
Summary statistics (mean, SD, and RMS of z-score) with the results of the t-test for the differences in kinematic, time, and distance parameters between both groups are shown in Table  II . Kinetic and EMG parameters are not included because they did not differ significantly between the groups. The control group showed a significantly increased mean anterior tilt (p<0.05) compared with the BTX-A group and a decreased hip extension at terminal stance (p<0.05), corresponding to a more pronounced pathological pattern (higher RMS of pathological z-score). All hip angles in the sagittal plane indicated a more pronounced flexion pattern (with a higher RMS of pathological z-scores) for the control group. Mean hip abduction/ adduction in swing was significantly different between the groups, again indicating a more pronounced, pathological pattern for the control group (p<0.05). The rotational deformities at the hip level (namely internal rotation at initial contact, Degrees toe-off and mid-swing) were significantly more pronounced in the control group (p<0.01, p<0.05, and p<0.005 respectively), resulting in a more pronounced internal foot alignment than in the BTX-A group. The RMS of the pathological z-score showed the BTX-A group to have a more normal gait pattern (lower RMS of pathological z-scores) than the controls for all the significantly different gait parameters. In addition, the control group often showed greater variance than the BTX-A group (Fig. 1) .
Discussion BTX-A use as an effective therapeutic tool for lower limb management in children with CP has been established, in particular, for the treatment of mild gait problems (equinus gait) and functional improvements in less-impaired children. 16 Several investigators have reported on the short-term clinical outcome of BTX-A treatment, expressed as improvements in passive range of motion and the amount of spasticity measured in clinical examination, [17] [18] [19] and on more functional outcomes through Gross Motor Function Measure [19] [20] [21] and gait evaluation. 13, 17, [22] [23] [24] However, so far there have been no long-term studies of functional outcome for the use of BTX-A in children with CP, and much remains unknown or poorly understood regarding the influence of conservative treatment on the natural history of children with CP. None of the reported studies compared the motor development of a group of BTX-A-treated children combined with conservative treatment options with the motor capacities of a control group.
Our results suggest that children who received BTX-A treatment as part of their conservative treatment plan had a more normal gait pattern than the control group. The two groups showed similar distributions of known factors that could influence motor development, except in the use of day orthoses, which were used more intensively in the BTX-A group. 9, 13, 23 The groups in this study were treated identically, with the exception of BTX-A, and in accordance with the same strategies, implying that all children received appropriate individualized sessions of physiotherapy, occupational therapy, and orthotic management. The pathological pattern at the level of the pelvis and hip in the sagittal plane was significantly less pronounced for the BTX-A group than for the control group. The anterior tilt of the pelvis and the amount of hip extension in stance can be related to the dynamic muscle length of the hip flexors. These findings suggest that a multilevel approach for BTX-A treatment has beneficial effects on the natural course of the length of proximal muscles. The better hip and knee extension in mid-stance in the BTX-A-treated children also indicates a lower incidence for crouch associated with BTX-A use. Knee flexion at initial contact was similar for both treatment groups. A crouch gait pattern, characterized by increased knee and hip flexion in stance, is often caused by shortening of the hamstrings, but crouch patterns can occur after Achilles tendon lengthening. Four children in the control group had a clinical history with isolated Achilles tendon lengthening that might have influenced the amount of knee flexion in stance.
Triceps surae contractures are known to be the major cause of deviated ankle rockers. Results from this study showed that BTX-A treatment had a beneficial effect on three ankle rockers at the ankle joint. There was a tendency to reduced plantar flexion at initial contact, increased maximal dorsiflexion in stance, and an increased ankle range of movement during push off for the children in the BTX-A group.
Conclusion
The gait pattern of the control group in the sagittal plane was characterized by a clearer crouch pattern with pelvic anterior tilt and pathological ankle rockers than in the BTX-A group. The more normalized ankle motion, along with the improved knee and hip kinematics at the end of stance (expressed as lower RMS of pathological z-scores) found for the children treated with BTX-A indicates that the gait pattern is less defined by muscle contractures at the level of the hip, knee, and ankle. The gait deviations in the transverse plane (i.e. internal hip rotation at initial contact, toe-off, and midswing) were significantly more pronounced in the control group. These results suggest that children treated with BTX-A have a gait pattern that is less defined by bony deformities common in spastic CP, which once established can be successfully managed only with orthopaedic surgery.
This study provides evidence of a prolonged effect of repeated multilevel BTX-A treatments on the walking pattern of children with CP. There are indications that BTX-A treatments, started at a young age and combined with common conservative treatment options, help to prevent muscle contractures and severe bony deformities. The BTX-A treatment programme reduces tone and encourages a more normalized motion, facilitating adequate stretch to the muscles that need to be elongated. Optimally-timed multilevel BTX-A injections, combined with physiotherapy and orthotic management, help to normalize motion, thereby improving proprioception, selective motor control, and strength, resulting in a higher functional performance. They may also reduce the complexity of surgery at a later age. 3, 9, 12 Moreover, effective conservative treatment also enhances patients' quality of life.
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